Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bTAE-HAIC Combined With Lenvatinib and Camrelizumab for Huge HCC
NCT06061276Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenvatinib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 6 months. Started May 2024; status: recruiting.
02
Drugs
lenvatinibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06061276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06061276.